Merck & Co., Inc. (MRK)
| Market Cap | 199.25B |
| Revenue (ttm) | 64.17B |
| Net Income (ttm) | 17.12B |
| Shares Out | 2.52B |
| EPS (ttm) | 6.74 |
| PE Ratio | 11.75 |
| Forward PE | 8.84 |
| Dividend | $3.16 (3.99%) |
| Ex-Dividend Date | Mar 17, 2025 |
| Volume | 13,396,615 |
| Open | 81.46 |
| Previous Close | 77.55 |
| Day's Range | 76.36 - 79.44 |
| 52-Week Range | 75.96 - 134.63 |
| Beta | 0.42 |
| Analysts | Buy |
| Price Target | 119.86 (+51.38%) |
| Earnings Date | Apr 24, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $119.86, which is an increase of 51.38% from the latest price.
News
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
Final Trade: DAL, MRK, GS, HII
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Walser Wealth's Rebecca Walser likes Alibaba and Merck as stocks protected from tariffs
iFi AI CEO Ron Insana and Walser Wealth's Rebecca Walser, join 'Power Lunch' to discuss the market sell-off, opportunities amid tariff climate and more.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Merck To Contact Him Directly To Discuss Their Options If you purchased or acquired s...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck & Co., Inc. Lawsuit - MRK
NEW YORK , April 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK). Shareholders who purchased shares of MRK during the class per...
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squ...
Why drug stocks are no longer a safe haven from the stock market's turmoil
Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options
S&P 500: Pharma Giants Lead Decline as Tariff Threats Rattle Pfizer, Merck, Johnson & Johnson
Pharmaceutical stocks tumble as Trump announces imminent “major tariff” on imported drugs. Pfizer, Merck, and Johnson & Johnson shares drop over 4%, dragging the broader S&P 500 lower.
Global pharma shares plunge as Trump doubles down on tariff threat
Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (April 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. The market is volatil...
Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath
Potato maker Lamb Weston Holdings Inc., telecom giant Verizon Communications Inc., drug maker AbbVie Inc. and retailer TJX Cos. all bucked a sharp market selloff Thursday, as Wall Street turned to sto...
My Top 10 High-Yield Dividend Stocks For April 2025
Q1 2025 ended negatively for SPY and VYM, but my watchlist outperformed, limiting losses to 1.38% and achieving a YTD gain of 1.89%. Since inception, my watchlist has a CAGR of 15.83%, outperforming S...
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk, ...
Dogs Of The Dow Chase April's 'Safer' Buy
Verizon is the only Dow Dog currently meeting the ideal of annual dividends from $1K invested exceeding its single share price. Analysts forecast net gains of 13.06% to 37.60% for the top-ten Dow Dogs...
Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24.
Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib
SHANGHAI , March 31, 2025 /PRNewswire/ -- On April 1, 2025 , Beijing Time, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization optio...
Merck plans US to launch subcutaneous version of Keytruda on October 1
Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption rates ...